- 作者: Austin W. T. Chiang, Hratch M. Baghdassarian, Benjamin P. Kellman, Bokan Bao, James T. Sorrentino, Chenguang Liang, Chih-Chung Kuo, Helen O. Masson and Nathan E. Lewis
- 作者服務機構: 1.Department of Pediatrics, University of California, 9500 Gilman Drive MC 0760, La Jolla, San Diego, CA, 92093, USA 2.The Novo Nordisk Foundation Center for Biosustainability at the University of California, La Jolla, San Diego, CA, 92093, USA 3.Bioinformatics and Systems Biology Graduate Program, University of California, La Jolla, San Diego, CA, 92093, USA 4.Department of Bioengineering, University of California, La Jolla, San Diego, CA, 92093, USA 5.The National Biologics Facility, Technical University of Denmark, Kongens Lyngby, Denmark
- 中文摘要:
- 英文摘要:
Cancer immunotherapy has revolutionized treatment and led to an unprecedented wave of immuno-oncology research during the past two decades. In 2018, two pioneer immunotherapy innovators, Tasuku Honjo and James P. Allison, were awarded the Nobel Prize for their landmark cancer immunotherapy work regarding “cancer therapy by inhibition of negative immune regulation” –CTLA4 and PD-1 immune checkpoints. However, the challenge in the coming decade is to develop cancer immunotherapies that can more consistently treat various patients and cancer types. Overcoming this challenge requires a systemic understanding of the underlying interactions between immune cells, tumor cells, and immunotherapeutics. The role of aberrant glycosylation in this process, and how it influences tumor immunity and immunotherapy is beginning to emerge. Herein, we review current knowledge of miRNA-mediated regulatory mechanisms of glycosylation machinery, and how these carbohydrate moieties impact immune cell and tumor cell interactions. We discuss these insights in the context of clinical findings and provide an outlook on modulating the regulation of glycosylation to offer new therapeutic opportunities. Finally, in the coming age of systems glycobiology, we highlight how emerging technologies in systems glycobiology are enabling deeper insights into cancer immuno-oncology, helping identify novel drug targets and key biomarkers of cancer, and facilitating the rational design of glyco-immunotherapies. These hold great promise clinically in the immuno-oncology field. - 中文關鍵字:
- 英文關鍵字: Glycosylation machinery, Cancer immunotherapy, CAR-T cell therapy, Immune checkpoint, Systems glycobiology, And Glyco-immunotherapy